Nuritas has initiated a double-blinded randomized controlled trial (NCT07528469) to evaluate the efficacy of PeptiStrong, a fava bean-derived peptide, in enhancing muscle strength among healthy adults aged 60 to 85. In collaboration with Liverpool John Moores University and StudySetGo, the trial will compare the effects of 2.4 g PeptiStrong plus 10 g whey protein against 20 g whey protein alone. The study, set to enroll 80 participants over 30 days, will primarily assess grip strength while also measuring secondary outcomes such as gait speed, chair stand performance, balance, body composition, quality of life, fatigue, and inflammatory markers. Results are anticipated in Q3 2026.

The significance of this trial lies in its potential to address age-related muscle decline, a critical factor in maintaining healthspan in older adults. By focusing on bioactive peptides and their role in muscle strength, Nuritas is leveraging its AI-driven approach to peptide discovery, which has been substantiated by three prior clinical studies. This aligns with current research trends emphasizing the importance of nutraceuticals in geriatric health, particularly in combating sarcopenia and improving overall functional capacity in aging populations.

The implications of this research extend to therapeutic strategies in aging biology, particularly in the development of targeted interventions for muscle preservation. If successful, this trial could shift current paradigms by integrating nutritional interventions with traditional exercise regimens, potentially influencing drug development timelines for age-related conditions. Furthermore, Nuritas’ expansion into European markets through new partnerships underscores the growing recognition of peptide-based therapies in enhancing healthspan, paving the way for broader applications in clinical practice.

Source: longevity.technology